Epitalon Research Overview: Telomere Peptide Mechanism & Dosing Notes

Epitalon research overview: telomerase activation mechanism, pineal peptide background, typical research dosing context, and storage notes for this longevity compound.

TL;DR

• Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a pineal gland extract studied by Khavinson's group in St. Petersburg
• Primary proposed mechanism: telomerase activation via TERT gene upregulation, with secondary effects on melatonin synthesis and antioxidant defense
• Typical research dose range: 5–10 mg per day via subcutaneous injection, course-based (10–20 consecutive days, 1–2 courses per year)
• Half-life is short (~15 minutes intranasal); subcutaneous dosing extends active window; course-based design reflects proposed epigenetic mechanism

Disclaimer: This article is intended for educational and research purposes only. Epitalon is not approved by the FDA for human therapeutic use. Research discussed here is primarily from Russian academic institutions and has not been replicated in large-scale Western clinical trials. Nothing here constitutes medical advice.

What Epitalon Is

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine), molecular weight 390.35 Da. It was synthesized as a molecular mimetic of epithalamin — a pineal gland extract studied by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology since the 1970s.

The pineal gland connection is biologically significant. The pineal gland regulates circadian biology through melatonin secretion and is proposed to influence aging through neuroendocrine mechanisms. Rather than working with crude epithalamin extract, Khavinson's team isolated the minimal active sequence and produced it as a pure compound. This is the research logic behind Epitalon's development. Epitalon is one of the most widely studied compounds in the longevity peptides category, alongside mitochondria-derived peptides such as MOTS-c, SS-31, and Humanin.

Unlike most research peptides that act through direct receptor binding, Epitalon is proposed to operate through epigenetic and transcriptional mechanisms — influencing gene expression rather than directly activating a receptor. This distinction explains why the research is designed around course-based protocols rather than chronic daily dosing: downstream gene expression changes may persist well after the compound has cleared.

Mechanism

Epitalon's primary proposed mechanism is activation of telomerase through upregulation of TERT (Telomerase Reverse Transcriptase), the catalytic subunit of the telomerase enzyme complex. Telomerase rebuilds telomere length at chromosome ends, counteracting the progressive shortening that occurs with each cell division. In most somatic cells, TERT expression is suppressed after early development — which is why telomeres shorten with age and why telomere length is used as a cellular aging biomarker.

A 2003 study by Khavinson et al. in Bulletin of Experimental Biology and Medicine reported increased TERT expression and telomerase activity in human fetal fibroblast cultures treated with Epitalon, with treated cells showing elongated telomeres compared to untreated controls. This was one of the first reports of pharmacological telomerase activation in human cell lines without genetic manipulation.

The proposed mechanism for TERT upregulation involves Epitalon acting as a peptide bioregulator — short peptides that bind directly to DNA or chromatin-associated proteins to modulate gene expression. Khavinson's group has published evidence of Epitalon interacting with histones and influencing chromatin structure, which provides a plausible mechanism for broad gene expression changes without receptor binding.

Beyond telomerase, Epitalon has been associated with stimulating melatonin synthesis in the pineal gland and upregulating antioxidant defense systems — effects that may contribute to observed outcomes independently of telomere biology.

Typical Research Dosing

Epitalon research uses a course-based approach rather than chronic daily administration. The standard design involves concentrated daily injections for 10–20 consecutive days, followed by months without dosing, with courses repeated 1–2 times per year.

Two common protocol variants are found in the published literature:

• 5 mg/day for 20 consecutive days (100 mg total per course)
• 10 mg/day for 10 consecutive days (100 mg total per course)

Both deliver the same 100 mg total per course, suggesting researchers consider total course dose the key variable. Administration is subcutaneous, typically as a single daily injection.

The rationale for course-based dosing is that Epitalon's proposed epigenetic mechanism produces durable downstream gene expression changes that persist after the compound has cleared. Chronic daily dosing is considered unnecessary under this model. The half-life via intranasal route is approximately 15 minutes; subcutaneous injection provides a longer active window, but the course-based design reflects mechanism rather than pharmacokinetics.

Reconstitution

Calculate your Epitalon dose → Peptide Reconstitution Calculator | Half-Life Calculator

A 10 mg vial reconstituted with 2 mL bacteriostatic water yields a concentration of 5,000 mcg/mL (5 mg/mL). At this concentration:

• 5 mg dose = 1.0 mL = 100 units on a U-100 insulin syringe
• 10 mg dose = 2.0 mL (exceeds practical single-injection volume)

For the 5 mg/day protocol, the 10 mg/2 mL reconstitution provides a clean 100-unit draw per injection. For a 10 mg/day protocol, reconstituting in 1 mL (10 mg/mL) yields 100 units per injection — the maximum practical subcutaneous volume.

→ Calculate Epitalon syringe units

Storage

Lyophilized (unreconstituted): Store at -20°C for long-term storage (up to 24 months). Short-term peptide storage at 4°C is acceptable for vials to be used within the next few weeks. Epitalon's small tetrapeptide structure is relatively stable — it lacks disulfide bonds and oxidation-sensitive residues — making it more robust than many larger peptides.

After reconstitution: Store at 2–8°C in bacteriostatic water; stability is typically 6–8 weeks. Never freeze a reconstituted solution. Protect from light during storage and handling. Because Epitalon courses involve 10–20 consecutive daily injections, reconstituting one vial at a time minimizes storage duration and preserves compound integrity throughout the course.

Frequently Asked Questions

Q: What is epitalon used for in research? A: Epitalon is studied primarily as a longevity and anti-aging compound, with the central hypothesis that it activates telomerase via TERT upregulation — potentially slowing or partially reversing telomere shortening. It is also studied for effects on pineal gland function, melatonin synthesis, and antioxidant defense. Most of the research comes from Khavinson's group in St. Petersburg and has not been replicated in large-scale Western trials.

Q: How is epitalon administered? A: Epitalon is administered subcutaneously (or occasionally intramuscularly) as a daily injection during a research course. Intranasal administration has also been reported. The standard research protocol calls for daily injections for 10–20 consecutive days, with courses repeated 1–2 times per year rather than chronic ongoing dosing.

Q: How long does an epitalon cycle typically run? A: A standard Epitalon course runs 10–20 consecutive days. The 10-day course uses 10 mg/day; the 20-day course uses 5 mg/day. Both deliver 100 mg total. After the course ends, no further dosing is used until the next course, which may be months later. This episodic structure distinguishes Epitalon from most other research peptides that are dosed continuously.

→ View Epitalon in the Peptide Database

This content is intended for research and educational purposes only. Epitalon is not approved for human therapeutic use. All research use should comply with applicable regulations.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions